Cellgate, Inc.

Wisconsin Alumni Research Foundation

Slil Biomedical, Corporation

Other

Progen Pharmaceuticals, Inc.

The United States of America As Represented by the Department of Health

Pathologica LLC

Laurence J Marton

Benjamin J Frydman

Andrei V Blokhin

Aldonia L Valasinas

Venodhar K Reddy

Hirak S Basu

Karen Neder

Yu Albert Wang

Donald T Witiak

Aparajita Sarkar

Linda Clifford, Legal Representative

Jerry Shunneng Sun

M Eileen Dolan

Keijiro Samejima

Burt Feuerstein

Hirak Subhra Basu

Michael S McGrath

Tennore M Ramesh

Sean Scott

Vendohar K Reddy

Subhra Bhattacharya

Oligoamine compounds with anti-cancer and anti-proliferative activity are provided, as well as methods for making and using the compounds. The compounds are shown to be active against prostate cancer cell lines and against prostate cancer tumors in mice. The compounds are also useful in treatment of breast cancer and other cancers.

Oligoamine compounds and derivatives thereof for cancer therapy

Conformationally restricted polyamine compounds useful in treatment of cancer and other diseases marked by abnormal cell proliferation are disclosed. Improved methods of synthesizing such compounds are also disclosed. In one method of the invention, a carbene-bearing or carbene equivalent-bearing compound is reacted with the double bond of an alkene compound to form a cyclopropyl ring as the first step in the synthesis.

Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor

Conjugates in which polyamine analogs are conjugated to an amino acid are provided, as well as compositions comprising these conjugates. Methods of using these conjugates as anticancer treatments are also provided.

Polyamine analog-amino acid conjugates useful as anticancer agents

Peptide conjugates in which cytocidal and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as compositions comprising these conjugates. Methods of using these conjugates in the treatment of prostate diseases are also provided.

Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases

Novel quinones are provided, as well as compositions comprising these novel quinones. Methods of using the novel quinones in treatment of various indications including cancer are also provided.

Quinones as disease therapies

The invention provides methods of monitoring amyotrophic lateral sclerosis (ALS) disease development or progression and monitoring an ALS therapy by determining the level of HLA-DR expression by CD14+ monocytes and/or the percentage of CD16+ cells in the population of CD14+ cells and/or the number of CD14+/CD16+ cells in peripheral blood of an individual with ALS. The invention is also directed to methods for decreasing the number of circulating CD14+ monocytes and/or the population of CD14+/CD16+ cells and/or the number of CD14+/CD16+ cells in an individual with ALS. The invention is also directed to methods of screening for agents which decrease the population of CD14+ monocytes with elevated HLA-DR expression and/or the population of CD14+/CD16+ cells and/or the number of CD14+/CD16+ cells in an individual with ALS.

Screening for agents effective in decreasing abnormal macrophages associated with amyotrophic lateral sclerosis

Novel conformationally restricted polyamine analogs are provided, as well as compositions comprising these novel polyamine analogs. Methods of using the novel polyamine analogs in treatment of diseases such as cancer are also provided. Also provided is a method of delivering these analogs specifically to tumor cells by covalently attaching polyamine analogs to porphyrin compounds, along with novel polyamine-porphyrin covalent conjugates.

Conformationally restricted polyamine analogs as disease therapies

Porphyrin-polyamine conjugate compounds are disclosed which have anticancer and antitumor effects. The porphyrin moiety selectively localizes in tumors, while the polyamine moiety serves as a cytotoxic agent. Methods of making and using the porphyrin-polyamine conjugate compounds are also disclosed.

Porphyrin-polyamine conjugates for cancer therapy

Novel conformationally restricted polyamine analogs are provided, as well as compositions comprising these novel polyamine analogs. Methods of using the novel polyamine analogs in treatment of diseases such as cancer are also provided. Also provided is a method of delivering these analogs specifically to tumor cells by covalently attaching polyamine analogs to, porphyrin compounds, along with novel polyamine-porphyrin covalent conjugates.

Conformationally restricted polyamines

Growing community of inventors

Palo Alto, CA, United States of America

Laurence J Marton